Sinovac Biotech Ltd. Engages The Ruth Group as Investor Relations And Public Relations Counsel

Sinovac Biotech Ltd. Engages The Ruth Group as Investor Relations And Public Relations Counsel

October 16, 2006

    BEIJING, Oct. 16 /Xinhua-PRNewswire/ -- Sinovac Biotech
Ltd. (Amex: SVA), a leading provider of biopharmaceutical
products in China, announced today that it has engaged The
Ruth Group (TRG), based in New York City, to serve as the
Company's investor relations and public relations counsel.

    Mr. Weidong Yin, President and CEO of Sinovac, stated,
"We expect that The Ruth Group will play a major role
in facilitating communications with Sinovac's U.S. investor
base.  Given their strong and broad experience in the
biotechnology and pharmaceutical sectors, their familiarity
with the information needs of the investment and media
communities, and their time zone availability, we
anticipate that they will add value by Sinovac's
communications program." 

    Carol Ruth, President and CEO of The Ruth Group, Inc.,
said, "We are pleased to add Sinovac to our quality
base of healthcare clients for which we provide investor
and public relations counsel and best-in-class program
implementation."

    About The Ruth Group

    Consistently ranked as one of the top U.S. financial
IR/PR agencies, The Ruth Group, based in New York, focuses
on serving the communications needs of biotechnology,
pharmaceutical, medical device, technology and
semiconductor companies.  Services include investor
relations, public relations, management counsel, corporate
positioning, pre-IPO public relations programs, media
relations and venture capital relations.  For more
information visit http://www.theruthgroup.com .

    About Sinovac 

    Sinovac Biotech Ltd. is a China-based biopharmaceutical
company that focuses on the research, development,
manufacture and commercialization of vaccines that protect
against human infectious diseases. Sinovac's vaccines
include Healive(TM) (hepatitis A), Bilive(TM) (combined
hepatitis A and B) and Anflu(TM) (influenza). Sinovac is
currently developing human vaccines against the H5N1 strain
of pandemic influenza, Japanese encephalitis and SARS.
Additional information about Sinovac is available on its
website, http://www.sinovac.com . To be added to our
distribution list, please email: [e-mail]. 
 
    Safe Harbor Statement 

    This announcement contains forward-looking statements.
These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will,"
"expects," "anticipates,"
"future," "intends," "plans,"
"believes," "estimates" and similar
statements. Among other things, the business outlook and
quotations from management in this press release contain
forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's
beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and
uncertainties. A number of important factors could cause
actual results to differ materially from those contained in
any forward-looking statement. Sinovac does not undertake
any obligation to update any forward-looking statement,
except as required under applicable law. 

    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   [phone] x871
     Fax:   [phone]
     Email: [e-mail]

    Investors/Media:

     Stephanie Carrington / Janine McCargo
     The Ruth Group
     Tel:   [phone]
     Email: [e-mail] /
[e-mail]

SOURCE  Sinovac Biotech Ltd.